**MINUTES**

**CPIC CONFERENCE CALL**

DATE: September 4, 2014

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping Announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a doodle link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link after each conference call. |
| CPIC SOP Changes | Changes to CPIC SOP were discussed. Description of the CPIC levels, additional information regarding Conflict of Interest for authors of CPIC guidelines, and description of how to construct Clinical Decision Support workflow figures and translation tables for the supplement (including examples) were added. The revised SOP has been uploaded to the CPIC working group site (http://consortia.pharmgkb.org/display/cpic/CPIC). | If you have any questions or comments, please contact Kelly (Kelly.caudle@stjude.org). |
| Genetic Testing Registry (GTR) summaries | The GTR has asked if CPIC could add a sentence on the monthly minutes requesting expert reviewers for the Medical Genetic Summaries developed by NCBI that are related to pharmacogenetic phenotypes. Members agreed this was okay. This will not be considered a CPIC activity but reviewers will be independently acknowledged (see <http://www.ncbi.nlm.nih.gov/books/NBK127547/> for example). The first summaries that need reviewers are: “Maraviroc Therapy and CCR5 Genotype” and “Gentamicin Therapy and MT-RNR1 Genotype”. Please contact Adriana Malheiro (Adriana.malheiro@nih.gov) if you are interested in reviewing. | Contact Adriana Malheiro (adriana.malheiro@nih.gov) with any questions. |
| CPIC Informatics working group update | -CPIC informatics continues to work on translation tables being added to the CPIC guidelines. -On behalf of Bob Freimuth, a conference was announced, “Representation of Genomic Test Results.” This workshop will use clinical use cases to explore current methods for reporting genetic test results, the challenges that variability in those methods present for the exchange and use of genetic data, and the impact that this variability has on patient care and translational research. Conference info is available at http://individualizingmedicineconference.mayo.edu/. | James, Michelle, and Bob will continue to update CPIC group on progress. |
| New Guidelines | We will soon be starting new guidelines focused on *CYP2C19*/voriconazole and *CYP2D6*/ondansetron. Authorship plans are underway. | Kelly will follow-up on progress |
| *UGT1A1*/atazanavir | Dr. David Haas, Vanderbilt University, discussed *UGT1A1* and atazanavir. Atazanavir is an antiretroviral drug of the protease inhibitor class used as first-line treatment of HIV. Individuals homozygous for *UGT1A1\*28* are at increased risk of developing hyperbilirubinemia leading to non-adherence due to symptoms (*i.e.* jaundice eyes, yellow skin, etc.). He discussed a study (in review) concluding that patients homozygous for *UGT1A1\*28* were at higher risk of bilirubin-related atazanavir discontinuation. Dr. Relling nominated this gene/drug as a new guideline topic. Members agreed. Dr. Haas agreed to serve as the senior author. | Kelly will follow-up with the Steering Committee to approve topic. If you have expertise in the topic and/or would like to nominate yourself or other individuals to participate as an author, please email Kelly (Kelly.caudle@stjude.org). |
| CPIC survey | -Kelly discussed the CPIC survey results conducted this summer. Fifty-seven respondents (41 CPIC members and 16 non-members; majority work for nonprofit or academic hospital or clinic) were asked questions regarding the utility of CPIC guidelines at their institution. A majority of respondents are using CPIC guidelines to “facilitate implementation of pharmacogenetics at my practice site” and “facilitate interpretation of genetic test results” as well as for educational/teaching resources. Respondents were also asked to rank genes/drugs for their utility as the subject of a new CPIC guideline. CPIC will use these results to help prioritize new gene/drug guideline topics. -CPIC is also considering creating an email update service. Emails would be sent to those who sign up (a) immediately for any guideline updates posted to PharmGKB that affect prescribing recommendations and are not part of published updates (estimate 1-5 per year) and (b) no more than once per month for other news and solicitation of feedback. We asked respondents if they would be willing to subscribe and 95.8% agreed.  | Kelly will follow-up about new email update service. |